ST段抬高型急性冠脉综合征临床路径的实施与效果评价

Abstract
Figure/Table
References (16)
Related Citation (6)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of the clinical approach of ST-segment elevation acute coronary syndrome.Methods 120 patients weres selected as research subjects,who was in ST-segment elevation acute coronary syndrome in our hospital from January 2013 to December 2016.The patients were divided into control group and CP group according to before and after the implementation of standardized rescue,with 60 cases in each group.For the control group to take routine treatment,CP group was based on our hospital′s own STE-ACS clinical path for diagnosis and treatment.The hospitalization time,average hospitalization cost,average drug cost and satisfaction degree were choosed as an evaluation indexs.Results CP group effective rate was 95.0%higher than the control group′s 86.7%(P＜0.05).The average hospital stay was(10.97±2.11)day in the CP group and(13.32±25)day in the control group(P＜0.05).The average cost of CP group was(7224.28±106.23)yuan,and the average cost of the control group was(8319.23±16.35)yuan(P＜0.05).CP group′s satisfaction was 96.67%,control group′s satisfaction was 81.67%(P＜0.05);CP group′s adverse reaction rate was 1.67%,the control group was 6.67%(P＜0.05).Conclusion Clinical application of the clinical pathway in patients with ST-segment elevation acute coronary syndrome(STE-ACS)was expected to be satisfactory.Not only improve the quality of medical care,but also shorten the number of hospital days,reduce the cost of hospitalization,in line with China′s national conditions.CP can be better improve the quality of medical care,protect medical security,standard medical charges,save health resources,improve patient satisfaction,Can be widely used in clinical practice.

Key words： ST-segment elevation acute coronary syndrome Clinical pathways Implementation Effect evaluation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHOU Xu-feng
	XIE Dong-ming
	JU Yan-juan
	ZHONG Wen-ting
	ZHU Jin-hai

Cite this article:

ZHOU Xu-feng,XIE Dong-ming,JU Yan-juan, et al. Implementation and elevation of clinical pathway of ST-segment elevation acute coronary syndrome[J]. 中国当代医药, 2017, 24(28): 48-50.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I28/48

[1]	杨天芬.替罗非班冠脉内注射在急性ST段抬高型心肌梗死患者急诊PCI术中的临床应用研究[D].延安大学，2015.
[2]	任浩进，王丽岳，黄莉芳.ST段抬高型急性心肌梗死患者的BNP浓度与冠脉病变程度、PCI治疗预后的相关性研究[J].临床医学研究与实践，2017，2（3）：38-39.
[3]	王瑞钰，张清，沈健，等.低蛋白血症与急性ST段抬高型心肌梗死患者冠脉病变及预后的相关性研究[J].重庆医科大学学报，2017，42（2）：225-231.
[4]	赵彩虹，郭庆峰.急性冠脉综合征临床路径实施疗效分析[J].中西医结合心脑血管病杂志，2017，15（2）：248-250.
[5]	洪基格，张琴.心电图aVR导联ST段改变在急性冠脉综合征诊断中作用的研究进展[J].中国临床新医学，2016，9（5）：453-458.
[6]	杨建伟，陆剑嵘，宋培新，等.临床路径管理对急性冠脉综合征住院患者医疗质量的影响[J].现代医院管理，2017，15（2）：45-47.
[7]	毕斯努.临床路径在急性冠脉综合征诊治中的应用与评价[D].中南大学，2012.
[8]	卜海伟，刘静怡，王明慧，等.不同性别急性冠状动脉综合征患者临床特征及预后影响因素分析[J].中国介入心脏病学杂志，2017，25（2）：96-101.
[9]	闫晓临.多标记物联合对无ST段抬高的急性冠状动脉综合征患者危险分层的临床意义[D].河北医科大学，2005.
[10]	杜燕.急性冠脉综合征临床护理路径的建立与实施[J].中国医药科学，2015，5（2）：120-121.
[11]	李艳.急救护理路径在急性冠脉综合征PCI中的临床价值分析[J].中国社区医师，2015，21（14）：129-130.
[12]	高鹏.急性冠脉综合征的治疗新进展[J].中国卫生产业，2015，12（29）：196-198.
[13]	过云峰，高长征，陈彩萍，等.瑞舒伐他汀与阿托伐他汀在ST段抬高急性冠脉综合征患者经皮冠状动脉介入治疗中临床疗效的对比研究[J].实用心脑肺血管病杂志，2016，24（3）：135-137.
[14]	拓文，杜敏，孙敏，等.实施临床路径干预对急性冠状动脉综合征临床疗效观察[J].中国介入心脏病学杂志，2011，19（6）：339-343.
[15]	屈长宏.急性冠脉综合征炎症因子的临床意义[J].现代诊断与治疗，2005，16（3）：168-171
[16]	张景昆，赵运涛，吴涛，等.急性ST段抬高型心肌梗死患者急诊经皮冠状动脉介入术后早期ST段变化的意义[J].中国全科医学，2015，（27）：3270-3275.